cicaprost

Subscribe to Selected New Research on cicaprost

35 relevant articles (5 outcomes, 5 trials/studies) found for this Bio-Agent

Description: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer

Also Known As:

13,14-didehydro-16,20-dimethyl-3-oxa-18,18,19,19-tetradehydro-6-carbaprostaglandin I2; 5-(7-hydroxy-6-(3-hydroxy-4-methylnona-1,6-diynyl)-bicyclo(3.3.0)octan-3-yliden)-3-oxapentanoic acid; ZK 96480; ZK-96480; cicaprost dihydrochloride

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 07/17/1995 - "Using different treatment schedules, a pronounced reduction of the number of lung metastases was achieved by administration of cicaprost until the end of the experiment (from day 5 to day 35), whereas short-term treatments (from day 5 to day 15 or to day 25) were without significant effect" 01/01/1994 - "In conclusion, in addition to its dose-dependent effect on haematogenous metastasis, Cicaprost strongly inhibits lymph node metastasis." 01/01/1994 - "Moreover, metastasis to the contralateral axillary lymph node was completely inhibited by Cicaprost at all three doses tested" 01/01/1994 - "Whereas the median number of lung metastases in the controls was greater than 1000, Cicaprost at a dose of 0.1 mg/kg reduced the number of lung metastases to between 11 and 100" 01/01/1994 - "Cicaprost given in daily doses of 0.01, 0.03 and 0.1 mg/kg orally, reduced the number of lung metastases in a dose-dependent manner" Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/1997 - "Whereas starting treatment with Cicaprost on the day of tumor implantation was a characteristic feature of our previous investigations, the present study focused on the antimetastatic potency of Cicaprost in animals with established tumor growth" 01/01/1996 - "As primary tumor growth in vivo or proliferation in vitro remained unchanged by cicaprost, its mode of action seems to be related to one or more mechanisms of the metastatic process" 07/17/1995 - "Results also indicate that direct effects on tumor cells may contribute to the anti-metastatic action of cicaprost in spontaneously metastasizing tumors." 07/17/1995 - "In addition to its inhibitory potential in animals with advanced tumor disease, cicaprost showed anti-metastatic action when used in peri-operative treatment of animals whose primary tumors had been removed" 07/17/1995 - "Start of treatment with cicaprost immediately before tumor implantation was a characteristic feature of our previous investigations" Order ALL the reference details at left...
3.	Systemic Scleroderma (Systemic Sclerosis) 01/01/1993 - "In this pilot study, we investigated the clinical efficacy of and patient tolerance to two dosage levels of cicaprost (2.5 micrograms tds and 5 micrograms tds) in the treatment of Raynaud's phenomenon secondary to systemic sclerosis (SSc)" 01/01/1993 - "A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis." 05/01/1991 - "We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS" 05/01/1991 - "The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study." Order ALL the reference details at left...
4.	Hypercholesterolemia 10/01/1993 - "Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits." 01/01/1992 - "Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia." 01/01/1992 - "Oral cicaprost resulted in a significantly reduced aortic atheromatous plaque formation and partially prevented hypercholesterolemia-induced impairment of endothelium-dependent relaxations" 10/01/1993 - "The efficacy of the oral prostacyclin mimetic cicaprost in preventing atheromatous plaque formation was studied in an in vivo model of experimental hypercholesterolemia" 01/01/1992 - "Cicaprost treatment (5 micrograms/kg x d) largely prevented the hypercholesterolemia-related impairment of coronary vasodilation and nitric oxide release" Order ALL the reference details at left...
5.	Adhesions 01/27/1995 - "PGI2 iloprost and cicaprost inhibited both 12(S)-HETE- and TPA-enhanced adhesion to endothelium and subendothelial matrix as well as alpha IIb beta 3 expression on W256 cells" 01/27/1995 - "We have investigated the regulatory role of PGI2 and its stable analogs, i.e., iloprost and cicaprost, on 12(S)-HETE- and TPA-enhanced tumor cell integrin expression and adhesion" 11/01/1997 - "Semiquantitative rt-PCR measurements showed a marked decrease of TNF-alpha- and IL-1 beta-induced mRNA levels of both adhesion molecules after preincubation with cicaprost" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Messenger RNA (mRNA)
3.	Interleukin-1beta (Interleukin 1 beta)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	tyramine-deoxysorbitol
6.	Iloprost (Ventavis)
7.	Aspirin (Acetylsalicylic Acid)
8.	fluprostenol
9.	Cytostatic Agents
10.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)

Related Therapies and Procedures

1.	Lasers (Laser)

Best Treatments:
Research Summary Report
on Neoplasm Metastasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3046 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download